Dale E. Shuster

Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial

William D. Tap, Hans Gelderblom, Emanuela Palmerini et al. · The Lancet · 2019 · 474 citations · Full text

Medicine, Oncology, Pharmacology +5

Identification and prevalence of a genetic defect that causes leukocyte adhesion deficiency in Holstein cattle.

Dale E. Shuster, Marcus E. Kehrli, Mark R. Ackermann et al. · Proceedings of the National Academy of Sciences · 1992 · 370 citations · Full text

Agriculture, Animal Sciences, Genetics +9

Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study

Lorenza Rimassa, Eric Assénat, Markus Peck‐Radosavljevic et al. · The Lancet Oncology · 2018 · 349 citations

Medicine, Oncology, Pharmacology +11

Phase III Multinational, Randomized, Double-Blind, Placebo-Controlled Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Erlotinib Alone in Previously Treated Patients With Locally Advanced or Metastatic Nonsquamous Non–Small-Cell Lung Cancer

Giorgio V. Scagliotti, Joachim von Pawel, Silvia Novello et al. · Journal of Clinical Oncology · 2015 · 260 citations · Full text

Medicine, Oncology, Pharmacology +16

Phase II Study of Eribulin Mesylate, a Halichondrin B Analog, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane

Linda T. Vahdat, Brian Pruitt, Carol J. Fabian et al. · Journal of Clinical Oncology · 2009 · 245 citations · Full text

Medicine, Oncology, Pharmacology +15